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BACKGROUND & AIMS: Transoral esophagogastric fundoplica-
tion (TF) can decrease or eliminate features of gastroesophageal
reﬂux disease (GERD) in some patients whose symptoms persist
despite proton pump inhibitor (PPI) therapy. We performed a
prospective, sham-controlled trial to determine if TF reduced
troublesome regurgitation toa greater extent thanPPIs inpatients
with GERD. METHODS: We screened 696 patients with trouble-
some regurgitation despite daily PPI use with 3 validated GERD-
speciﬁc symptom scales, on and off PPIs. Those with at least
troublesome regurgitation (based on the Montreal deﬁnition) on
PPIs underwent barium swallow, esophagogastroduodenoscopy,
48-hour esophageal pHmonitoring (off PPIs), and high-resolution
esophageal manometry analyses. Patients with GERD and hiatal
hernias2 cmwere randomly assigned to groups that underwent
TF and then received 6 months of placebo (n ¼ 87), or sham
surgery and 6 months of once- or twice-daily omeprazole (con-
trols, n ¼ 42). Patients were blinded to therapy during follow-up
period and reassessed at 2, 12, and 26 weeks. At 6 months, pa-
tients underwent 48-hour esophageal pH monitoring and esoph-
agogastroduodenoscopy. RESULTS: By intention-to-treat
analysis, TF eliminated troublesome regurgitation in a larger
proportion of patients (67%) than PPIs (45%) (P¼ .023). A larger
proportion of controls had no response at 3 months (36%) than
subjects that received TF (11%; P ¼ .004). Control of esophageal
pH improved after TF (mean 9.3% before and 6.3% after; P <
.001), but not after sham surgery (mean 8.6% before and 8.9%
after). Subjects fromboth groupswho completed the protocol had
similar reductions in GERD symptom scores. Severe complica-
tions were rare (3 subjects receiving TF and 1 receiving the sham
surgery). CONCLUSIONS: TF was an effective treatment for pa-
tients with GERD symptoms, particularly in those with persis-
tent regurgitation despite PPI therapy, based on evaluation 6
months after the procedure. Clinicaltrials.gov no: NCT01136980.
Keywords: TIF; EsophyX; Stomach; Esophagus.astroesophageal reﬂux disease (GERD) remains oneGof the most common condition for which Americans
take daily medication, and proton-pump inhibitor (PPI) use
has more than doubled in the last decade.1 Despite this, up to
40% of PPI-dependent GERD patients have troublesome
symptoms of GERD, despite PPI therapy.2,3 Although laparo-
scopic antireﬂux surgery has been suggested for this group of
patients, fear of surgery, side effects, and recurrent symptoms
have kept patient and referring physician interest to<10% of
those otherwise qualifying for surgery.4,5 Transoral endo-
scopicmethods of treatingGERDhave been available formany
years, but only one of these technologies allows the creation of
a fundoplication, by folding the stomach anteriorly around the
esophagus and securing it with multiple fasteners. Although
this device has been in use for 9 years in Europe and 7 years in
the United States, and has been proven effective in registry
trials and one randomized controlled trial (RCT), comparison
of effectiveness in patients with persistent symptoms on PPI
has been absent.6–8 Our aimwas to determine whether or not
transoral fundoplication (TF)wasbetter thanPPI treatment of
troublesome GERD symptoms, particularly regurgitation, in a
population of chronic PPI-dependent GERD patients.
Methods
Ethics Statement
This study was approved by the Institutional Review Board
of each site and was conducted in accordance with the Good
Clinical Practices and Declaration of Helsinki. All patients pro-
vided written informed consent form. All authors had access to
the study data and reviewed and approved the ﬁnal manuscript.
Figure 1. Transoral fundoplication creates a 3 cm ﬂap valve,
180–270 degrees in circumference.
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The Randomized EsophyX vs Sham, Placebo-Controlled
Transoral Fundoplication (RESPECT) trial was carried out at
8 academic and community medical centers across the United
States. We recruited patients between the ages of 18 and 80
years with more than 6 months of GERD symptoms and trou-
blesome regurgitation, despite a minimum PPI dose of 40 mg
daily. Troublesome regurgitation was deﬁned as mild symp-
toms for 2 or more days per week or moderate to severe
symptoms more than 1 day per week, per Montreal consensus
criteria.3,9 Symptom assessment used the following 3 validated
tools: the Reﬂux Disease Questionnaire (RDQ), the Gastro-
esophageal Reﬂux Symptom Score, and the GERD-Health
Related Quality of Life on PPI and off PPI for at least 7 days.
Abnormal amounts of gastroesophageal reﬂux off PPI for 7 days
was conﬁrmed by distal esophageal pH <4 for >5.3% of at
least 1 of the 2 days that pH was measured with a Bravo
(radiotelemetry) probe (Given Imaging, Yoqneam, Israel). High-
resolution esophageal manometry conﬁrmed the absence of
esophageal motor dysfunction. Esophagogastroduodenoscopy
(EGD) was performed to grade the appearance of the antireﬂux
barrier (Hill grade), to conﬁrm the absence of long segment
Barrett’s esophagus, and to grade esophagitis, if present. Cine-
esophagography was performed to conﬁrm the absence of hi-
atal hernia or a hiatal hernia 2 cm in length. Exclusion criteria
included systemic disease not well controlled, obesity deter-
mined by body mass index >35, esophageal ulcer, stricture,
Barrett’s esophagus >2 cm in length, hiatal hernia >2 cm in
length, Los Angeles grade C or D esophagitis, esophageal dys-
motility, previous esophageal or gastric surgery, peptic ulcer
disease, gastric outlet obstruction, gastroparesis, pregnancy or
plans for pregnancy in the next 12 months, immunosuppres-
sion, portal hypertension, and coagulopathy. Patients were
randomized 2:1 to either TF (study group) or sham surgery
(control group). A computer-generated block-randomization
method was used to assign patients to study or control group.
After informed consent and administration of general anes-
thesia with endotracheal intubation, a sealed envelope, pro-
vided by an independent statistician, was opened by the
operating team that indicated group allocation.
Operative Procedure
Patients allocated to the TF group underwent a standard-
ized technique using the EsophyX-2 device (EndoGastric Solu-
tions, Redmond, WA) as described previously.10 The valve was
created with a minimum of 13 fasteners, and was at least 1 cm
long at either corner and 3 cm long in its mid-portion
(Figure 1). Each participating surgeon submitted a video of a
qualifying TF procedure that was reviewed and approved by
Hunter and Bell before enrolling patients into the trial
(Video 1). Patients in the control group had a sham procedure
performed for 45–60 minutes, which included EGD for 30 mi-
nutes, and passage of a 50F Maloney dilator for 15 minutes, to
simulate TF procedure and oropharyngeal irritation caused
by TF.
Postoperative Care and Follow-Up
Patients were kept in the hospital overnight and were
generally discharged the next day on omeprazole 40 mg for 14
days to help promote mucosal healing around fasteners if reﬂuxcontrol was incomplete. Thereafter, TF patients were switched
to placebo, and sham patients were continued on omeprazole
in an identical-appearing capsule. For the ﬁrst 2 weeks post-
operatively, patients were kept on a liquid diet. Soft foods were
given from weeks 3 to 7, and a regular diet was reinstated
2 months after the operative procedure. Neither the patient nor
their family was aware of allocation group until the 6-month
point, or when they were declared failures and allowed to
cross over to the other treatment arm. The perioperative
caregivers (other than the operative team) were unaware of
treatment allocation.
Follow-up occurred at weeks 2, 12, and 26 after TF or
sham procedure. If troublesome symptoms of GERD recurred
after 2 weeks, the medication dose was doubled (omeprazole
40 mg bid or placebo bid). If troublesome symptoms persisted
at 3 months, despite bid medication use, the patient was
declared a failure and the blind was broken. Once the blind
was broken, failed TF patients were given PPI and sham pa-
tients were offered TF both for ethical reasons and to make
study enrollment more attractive to potential participants
(Figure 2).
Figure 2. Study ﬂow chart.
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naires on and off medication (PPI or placebo), 48-hour esoph-
ageal pH monitoring off medications (7 days), and EGD.
After completion of these evaluation steps, the study was
considered complete. Symptomatic sham patients were offered
the opportunity to cross over to TF and TF patients with
troublesome symptoms were offered PPIs.Primary and Secondary End Points
The primary study end point was the elimination of trou-
blesome regurgitation, per Montreal consensus deﬁnition, on
placebo (TF group) and on PPI (control group). The Montreal
consensus deﬁnes troublesome symptoms as mild symptoms
occurring 2 or more days a week, or moderate to severe
symptoms occurring more than 1 day a week.2 The elimination
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instrument asks 12 questions addressing the symptom domains
of heartburn, regurgitation, and dyspepsia using a scale from
0 to 5 to rate the severity and frequency of 6 symptoms.11 A
severity score of 2 or more and a frequency score of 3 or more
for the regurgitation questions were required to meet the
Montreal consensus criteria for troublesome regurgitation, a
threshold supported by a recent analysis of the impact of
regurgitation on quality of life.9 Our primary hypothesis
was that the proportion of transoral fundoplication/placebo
patients who are relieved of troublesome regurgitation will be
statistically signiﬁcantly greater than those randomized to the
sham/PPI group.
Secondary end points included early failure (deﬁned as
moderate to severe regurgitation at any time >12 weeks after
surgery and after a doubling of medication, PPI, or placebo) and
control of intraesophageal acid exposure. Other secondary
outcomes assessed included improvement in various symptom
scores (particularly heartburn), healing of esophagitis, common
side effects associated with treatment (bloating and dysphagia),
and signiﬁcant adverse events.
Statistical Analysis
A sample size of 80 TF/placebo and 40 sham/PPI patients
was necessary for an 85% power to detect a signiﬁcant dif-
ference between the 2 treatment groups. Sample size was
determined assuming a 30% greater elimination of trouble-
some regurgitation with TF as compared with PPI, based on
previous reports.12 The primary study end point of elimination
of troublesome regurgitation was assessed using a c2 test.
Binary secondary outcomes were also assessed with a c2 test,
and continuous outcomes used a Wilcoxon matched pairs test
for comparisons between screening and end-of-study values or
a Mann-Whitney U test for comparisons between groups.
Spearman r statistics was used to estimate correlation between
postoperative pH parameters and symptom control as assessed
by the quality of life symptom scores.
The primary end point was analyzed using the intent-to-
treat population (ITT) and per protocol population. For the
ITT analysis, a patient was declared a treatment failure if the
3-month and 6-month follow-up visits were not completed.13 If
a patient reported insufﬁcient control of regurgitation on
increased dose of medication at 3-month visit, and missed the
6-month visit, the patient was considered a treatment failure.Results
Patient Population
Between June 2011 and September 2013, there were
3388 initial contacts made, mostly through web-based
announcement of the trial. Six hundred and ninety-six pa-
tients were screened for eligibility and 567 were excluded.
The most frequent reasons for exclusion were the presence
of hiatal hernia >2 cm, absence of troublesome regurgita-
tion, normal esophageal pH monitoring, and long segment
Barrett’s esophagus (Supplementary Figure 1). One hundred
and twenty-nine patients were randomized, underwent
sham surgery or TF, and were analyzed using the ITT
population. Upon review of the entry criteria, 10 patients
were excluded after treatment (6 in the TF arm and 4 in thesham arm), because they did not meet the entry criteria of
troublesome regurgitation, as deﬁned by Montreal criteria
(8 patients), or did not have an abnormal pH study (2 pa-
tients). Of these 10 patients, 2 of 6 (33%) in the TF/placebo
group and 2 of 4 (50%) in the sham/placebo group were
declared early failures (P > .999). These patients did not
receive 6-month follow-up with questionnaires and testing.
Therefore, the PP analysis includes 81 TF/placebo and 38
sham/PPI patients. One patient in each group was lost to
follow-up. The baseline and disease-related characteristics
of the ITT study population are shown in Table 1.Procedure
The mean operating time for TF was 49 minutes (range,
21–119 minutes). A mean of 23 fasteners was used (range,
13–37). As assessedby immediate post-procedure endoscopy,
performance of 270-degree fundoplication (range, 200–340
degrees) resulted in the conversion ofHill grade2 and3 valves
to Hill grade 1 in 79 of 82 (96%) patients. At discharge,
epigastric pain was the only symptom that occurred more
commonly in the TF than the sham group (34 of 83 vs 8 of 40;
P¼ .026). Signiﬁcant adverse events occurred in 7 patients in
the TF/placebo group, and 1 in the sham/PPI group (Table 2).
None of these events led to additional procedures, and all
resolvedwithout residual effect. Two patients with prolonged
epigastric pain where treated with over-the-counter pain
medication and did not report pain 4 weeks after TF.Follow-Up and Early Failure (Intention to Treat)
At 3 months follow-up, 15 of 42 patients (36%) in the
sham group met criteria for early failure, and 12 of 15 pa-
tients (80%) underwent crossover to TF. The 3 sham pa-
tients who had not crossed over completed the 6-month
follow-up testing. In the TF/placebo group 10 of 87 pa-
tients (11%) met the criteria for early failure (P ¼ .002) and
all 10 returned to PPI treatment. Four of these 10 patients
completed their 6-month follow-up testing. In total, 28 sham
patients and 76 TF patients completed 6-month evaluation
(Supplementary Figure 1).Primary Outcomes
In the ITT analysis at 6-month follow-up, 58 of 87 (67%)
TF/placebo patients reported the elimination of trouble-
some regurgitation vs 19 of 42 (45%) patients in the sham/
PPI arm (P ¼ .023).
The PP analysis revealed similar outcomes; 54 of 81
(67%) patients in the TF/placebo arm reported the elimi-
nation of troublesome regurgitation, and 17 of 38 (45%)
patients in the sham/PPI arm reported elimination of
troublesome regurgitation (P ¼ .028).Secondary Outcomes
As measured with the RDQ in those patients completing
their 6-month follow up, TF provided equivalent improve-
ment in symptom scores to sham/PPI on medication
(Figure 3). TF provided greater reduction in heartburn and
Table 2.Signiﬁcant Adverse Events
Randomization group Signiﬁcant adverse event Maximum severity Onset after procedure Duration
Sham Nausea Severe PPD 1 2 Days
TF Temporary epigastric /abdominal pain Severe PPD 5 2 Weeks
Chest pain Severe PPD 5 3 Days
Musculoskeletal pain Severe PPD 1 1 Day
Temporary epigastric /abdominal pain Moderate PPD 1 4 Weeks
Dysphagia Moderate PPD 1 8 Days
Dysphagia Mild PPD 1 1 Day
Nausea Mild PPD 1 1 Day
NOTE. Per-protocol deﬁnition, the events reported were classiﬁed as serious adverse events as they required in-patient
hospitalization or prolonged hospitalization. All reported serious adverse events resolved without residual effect.
PPD, post-procedure day; TF, transoral fundoplication.
Table 1.Demographics and Baseline Characteristics of the Study Patients
Variables TF/placebo (n ¼ 87) Sham/PPI (n ¼ 42) P value
Female, n (%)a 40 (45.9) 26 (61.9) .096
Age, y, median (range) 52 (2274) 55 (2273) .513
50 y, n (%)a 35 (40.2) 13 (30.9) .337
50–65 y, n (%)a 43 (49.4) 25 (59.5) .348
>65 y, n (%)a 9 (10.3) 4 (9.6) >.999
Body mass index, median (range) 27.1 (20.335.5) 27.8 (20.438.9) .326
<25, n (%) 22 (25.3) 10 (24.3) >.999
25–30, n (%) 45 (51.7) 19 (45.2) .574
>30, n (%) 20 (23.0) 13 (30.5) .391
GERD symptom duration, y, median (range) 10 (0.637) 10 (0.938) .546
PPI therapy duration, y, median (range) 9 (130) 8 (123) .541
Esophagitis (Los Angeles grade), n (%)a 17 (19.5) 6 (14.3) .625
Aa 10 (58.8) 3 (50.0) >.999
Ba 7 (41.2) 3 (50.0) >.999
Hill grade, n (%)a,b 86 (98.8) 41 (97.6) .547
Ia 4 (4.6) 5 (12.2) .147
IIa 57 (66.3) 26 (63.4) .842
IIIa 25 (29.1) 10 (24.4) .674
Hiatal hernia, n (%)a 60 (69.8) 29 (69.0) >.999
Axial length 1 cma 33 (55.0) 18 (62.1) .649
Axial length >1 cm and 2 cma 27 (45.0) 11 (37.9) .649
GTD, n (%)a
1 cm 20 (33.9)b 13 (46.4)b .345
>1 cm and 2 cma 36 (61.0)b 15 (53.6)b .642
>2 cma 3 (5.1)b 0 (0)b .548
RDQ score, median (range)
On PPIs 2.8 (1.14.8) 3.3 (0.95.0) .094
Off PPIs (n ¼ 85 TIF; n ¼ 40 sham) 3.3 (1.25.0) 3.6 (0.65.0) .085
GERD-HRQL score, median (range)
On PPIs 25 (041) 27 (745) .108
Off PPIs (n ¼ 85 TIF; n ¼ 40 sham) 29 (347) 31 (950) .450
GERSS, median (range)
On PPIs 22 (354) 27 (856) .052
Off PPIs (n ¼ 85 TIF; n ¼ 40 sham) 30 (560) 34 (960) .185
NOTE. Esophagitis, Hill grade were evaluated with screening endoscopy. Hiatal hernia size was graded with videoﬂuoroscopy.
P values were calculated using Mann-Whitney U test unless indicated otherwise.
GERD-HRQL, Gastroesophageal Reﬂux Disease Health-Related Quality of Life; GERSS, Gastroesophageal Reﬂux Symptom
Score; GTD, greatest transverse dimension; RDQ, Reﬂux Disease Questionnaire.
aTwo-tailed Fisher’s exact test.
bOne patient in the transoral fundoplication (TF)/placebo groupo and one patient in the sham/PPI group have a missing data
point.
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Figure 3. (A) Individual total regurgitation scores on placebo (TF group) and on PPI (sham group) in all patients undergoing
symptomatic assessment before treatments and at 6-month follow-up. (B) Individual total heartburn scores on placebo (TF
group) and on PPIs (sham group) in all patients undergoing symptomatic assessment before treatments and at 6-month
follow-up. (C) Individual total composite heartburn and regurgitation scores on placebo (TF group) and on PPIs (sham
group) in all patients undergoing symptomatic assessment before treatments and at 6-month follow-up. All scores were
assessed using RDQ. Red lines represent improvement in the median (25%, 75% quartiles) scores. The P values in boxes
represent comparisons between treatment groups.
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(Supplementary Figure 2).
TF was associated with signiﬁcant decrease in intra-
esophageal acid exposure in all parameters measured
(Figure 4). Mean number of reﬂux episodes fell from 135before TF to 94 after TF (P < .001). Mean percent total time
pH <4 improved from 9.3 before TF to 6.4 after TF
(P < .001). Mean DeMeester score fell from 33.6 before TF
to 23.9 after TF (P < .001). Of these 3 measures, only the
number of reﬂux episodes was normalized by the
Figure 4. Total number of reﬂux episodes (A), percent time pH <4 (B), and DeMeester Score (C) were improved in TF/placebo
group, but not in sham PPI group. The red lines represent change in mean scores. The green lines represent the cut-off for the
normal values (reﬂux episodes ¼ 100, percent total time pH <4 ¼ 5.3% and DeMeester Score ¼ 14.72). The P values in boxes
represent comparisons between treatment groups.
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pH control was detected, as measured with 48-hour pH
testing off PPIs for 7 days. Mean number of reﬂux episodeswere 125 before sham surgery and 122 after sham surgery
(P ¼ NS). Mean percent total time pH <4 was 8.6 before
sham surgery and 8.9 after sham surgery (P ¼ NS). Mean
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after sham surgery (P ¼ NS).
EGD revealed esophagitis in the minority of patients at
baseline (17 in the TF group and 6 in the sham group). Of 17
patients in the transoral fundoplication/placebo group who
had esophagitis on screening, 13 (76%) underwent endos-
copy at 6 months. Reﬂux esophagitis was healed in 10 of 13
(77%); esophagitis improved from grade B to A in an
additional 2 patients; in the last patient grade B esophagitis
remained unchanged. In the sham/PPI group, of 6 patients
with esophagitis on screening, 2 (50%) underwent endos-
copy at 6 months. Esophagitis was healed in 1 patient (50%)
improved from grade B to grade A in the other. At 6-month
follow-up, de novo esophagitis was present in 4 TF/placebo
patients (3 grade B and 1 grade A) and 5 sham/PPI patients
(3 grade B and 2 grade A) (P ¼ NS).
With the exception of postoperative epigastric pain,
complications, and adverse effects were not different be-
tween TF and sham groups. On medication, bloating and
dysphagia, as evaluated by Gastroesophageal Reﬂux Symp-
tom Score, were improved after the procedure in both TF
and sham groups (Supplementary Figure 3). One patient in
the TF group and 2 patients in the sham group developed de
novo dysphagia.
Including the early failures mentioned and follow-up out
to 18 months, 30 of 42 patients (71%) in the sham/PPI arm
have crossed over to TF. Including the early failures of TF
mentioned, 24 of 87 (28%) in the TF/placebo group have
resumed PPI (P < .001).Discussion
A variety of endoscopic devices have been introduced to
treat GERD over the past 2 decades. Most of these have been
removed from the market because they were ineffective or
unsafe. The only device available over the past 5 years that is
capable of creating an antireﬂux valve endoscopically is the
EsophyX device. Several case series and several registry re-
ports have guided the evolution of the TF technique with this
device.7,12,14–16 As is common, early case series of this new
surgical technique hadmixed results, but as more experience
was gained with the procedure, outcomes improved, and the
number of related complications decreased.6 One relevant
trend observed was that procedures using fewer fasteners
were associated with less favorable outcomes,17 an obser-
vation that led us to use a mean of 23 fasteners in this series.
A recent open-label randomized controlled trial comparing
PPI treatment with TF demonstrated beneﬁt for TF over PPI
in control of troublesome GERD symptoms, with 54% of
patients achieving normalization of intra-esophageal pH off
PPI after TF. Similar pH normalization was achieved with
high-dose PPI (on high-dose PPI), but GERD symptoms,
particularly regurgitation and atypical symptoms, were bet-
ter controlled with TF than with high-dose PPI.8
TheMontreal deﬁnition of reﬂux is eithermucosal damage
or troublesome symptoms attributable to reﬂux. Consistent
with this, we used the elimination of troublesome regurgita-
tion (deﬁned as that of sufﬁcient magnitude to impair quality
of life), rather than an improvement in regurgitation score asour primary endpoint. This approach has been recommended
in previous published literature on assessing regurgitation in
GERD management.9,18 The primary end point in this study,
elimination of troublesome regurgitation, was achieved in a
greater proportion of patients treated with TF than with
omeprazole: 67% vs 45%. That the reduction in composite
symptom scores associated with treatment show no statisti-
cal difference between treatment groups at 6 month
(Figure 3) is potentially confusing because these comparisons
do not include data from the early failures, a group that was
overrepresented in the sham/PPI treatment arm. Addition-
ally, reduction in a symptom score is not measuring the same
thing as the elimination of a troublesome symptom, andmight
yield different results, even if the populations queried were
identical.
Secondary end points included response of other symp-
toms to TF, using well-validated questionnaires, and objec-
tive testing (48-hour esophageal pH monitoring and EGD).
Evidence that TF was effective at improving GERD symp-
toms, heartburn, and regurgitation was well demonstrated
with the improvement in 6-month RDQ scores as compared
with baseline scores (Supplementary Figure 2). Improve-
ment of intra-esophageal acid control was greater after TF
than sham (Figure 4). Some studies evaluating TF,15 PPI
therapy,19 and traditional laparoscopic fundoplication20,21
demonstrated poor correlation between post-treatment pH
parameters and symptom control, as evaluated with various
disease-speciﬁc symptom scores. This study also found no
signiﬁcant correlation between objective and subjective
outcomes in either treatment group (Supplementary
Table 1). Although some studies have used pH normaliza-
tion as a primary end point, the elimination of troublesome
symptoms and the healing of reﬂux esophagitis are more
clinically relevant goals of GERD treatment; symptom control
might not require pH normalization. With traditional anti-
reﬂux surgery, there has long been the concern that reﬂux
control comes at the expense of new symptoms and side
effects (primarily dysphagia and bloating). This did not
appear to be the case in this study, as dysphagia and bloating
scores were improved in both treatment groups, and new
onset symptoms (dysphagia or bloating) were rare and
evenly balanced between groups (Supplementary Figure 3).
Reﬂux esophagitis was healed in 77% of TF/placebo
patients in this study, mirroring results from other recent
reports from the United States.7,15 However, these results
must be interpreted from the perspective that this study
was not designed to evaluate esophagitis healing and only a
limited number of enrolled subjects had esophagitis at en-
try; 17 patients in the TF/placebo group and 6 patients in
the sham/PPI group.
TF can ﬁll the “therapeutic gap” that exists between PPI
and laparoscopic fundoplication. Up to 40% of GERD pa-
tients have troublesome symptoms, despite adequately
dosed PPI.3 Although this group of patients might be treated
with laparoscopic fundoplication or the LINX device,22 the
absence of hiatal hernia or advanced esophageal disease
begs the question as to whether or not a less invasive and
more calibrated treatment might be available to ﬁll this gap.
When comparing this trial with those using the LINX device,
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randomized trial, that patients in this study had less
response to PPI therapy at baseline than in previously
published case series of LINX use (Table 1), and that TF
cannot effectively close a hiatal hernia, as is a part of the
LINX procedure in many patients. Both interventions seem
to have particular beneﬁt in improving the symptom of
regurgitation. Considering the virtual absence of dysphagia
and bloating after TF, which can be problematic with LINX,
it would appear that TF is an option for patients with
troublesome regurgitation, as well as for patients with
troublesome GERD symptoms who wish not to take PPI for a
protracted period of time.
This study was not designed to evaluate the cost-
effectiveness of TF compared with other treatments for
chronic GERD. Currently, it is unclear if the beneﬁt of TF
would offset higher upfront cost of TF as compared with
long-term PPI therapy. Higher upfront cost of TF can be
offset by improvement in patients’ quality of life and lower
health care utilization in patients who do not fully respond
to PPI therapy. Cost-effectiveness models can be developed
from these and other data when longer term follow-up be-
comes available.
There are several limitations to this study. Our ITT
analysis included 12 patients with limited follow-up data.
Assessment of the primary end point at 6 months can be
viewed as premature by some; however, we believed it
likely that delaying the primary end point beyond 6 months
would risk patients not entering or dropping out of the
study prematurely. That 15 of 42 (36%) patients in the
control group were early failures and 12 of these decided to
cross over to TF is further evidence that they felt incom-
pletely treated on escalating doses of PPI. Although there is
a plan to follow both groups of patients beyond 6 months,
the proof of efﬁcacy was achieved in a 6-month window.
Studies that have followed TF patients for more than 3 years
have demonstrated little deterioration in the response
measured shortly after operation.16 Screening of interested
patients eliminated about 81% of the patients who had
GERD symptoms on PPI. The most frequent reason for
exclusion was a hiatal hernia >2 cm, which eliminated 31%
of those screened. TF has been shown to be capable of
reducing hiatal hernias up to 2 cm in axial height, but
patients with hiatal hernias >2 cm in height and trouble-
some GERD symptoms despite appropriate medical therapy
should be considered for laparoscopic hiatal hernia repair
with fundoplication.23
In this sham-controlled randomized controlled trial,
transoral fundoplication was effective in eliminating trou-
blesome GERD symptoms, especially regurgitation, with a
low failure rate and good safety proﬁle for 6 months. We
believe TF has a role in treating GERD patients with small or
absent hiatal hernia who suffer from troublesome regurgi-
tation despite PPI therapy.Supplementary Material
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Supplementary Figure 1. CONSORT (Consolidated Standards of Reporting Trials) diagram.
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Supplementary Figure 2. (A) Individual regurgitation scores off placebo (TF group) and off PPIs (sham group) undergoing
symptomatic assessment before treatments and at 6-month follow-up. (B) Individual heartburn scores off placebo (TF group)
and off PPIs (sham group) in all patients undergoing symptomatic assessment before treatments and at 6-month follow-up. (C)
Individual composite heartburn and regurgitation scores off placebo (TF group) and off PPIs (sham group) in all patients
undergoing symptomatic assessment before treatments and at 6-month follow-up. All scores were assessed using RDQ. Red
lines represent improvement in the median (25%, 75% quartiles) scores. The P values in boxes represent comparisons be-
tween treatment groups.
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=Supplementary Figure 3. (A) Individual dysphagia scores on placebo (TF group) and on PPIs (sham group) in all patients
undergoing symptomatic assessment before treatments and at 6-month follow-up. (B) Individual bloating scores on placebo
(TF group) and on PPIs (sham group) in all patients undergoing symptomatic assessment before treatments and at 6-month
follow-up. (C) Individual dysphagia scores off placebo (TF group) and off PPIs (sham group) in all patients undergoing
symptomatic assessment before treatments and at 6-month follow-up. (D) Individual bloating scores off placebo (TF group)
and off PPIs (sham group) in all patients undergoing symptomatic assessment before treatments and at 6-month follow-up. All
scores were assessed using Gastroesophageal Reﬂux Symptom Score. Thickness of lines represents the number of patients
with the same initial and ﬁnal values. Red lines indicate the overall trend connecting the mean at screening and follow-up.
P values are from Wilcoxon matched pairs tests.
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Supplementary Table 1.Correlation Between pH Parameters and Symptom Scores in Both Treatment Groups
Parameters Regurgitation Heartburn R&H DMS % Total time NORE
TF group off placebo
Regurgitation 1.00
Heartburn 0.59 (<.001) 1.00
R&H 0.91 (<.001) 0.85 (<.001) 1.00
DMS 0.02 (.839) 0.14 (.249) 0.09 (.439) 1.00
% Total time 0.01 (.889) 0.15 (.213) 0.09 (.433) 0.99 (<.001) 1.00
NORE 0.03 (.771) 0.08 (.518) 0.07 (.556) 0.82 (<.001) 0.84 (<.001) 1.00
Sham group off Omeprazole
Regurgitation 1.00
Heartburn 0.50 (.009) 1.00
R&H 0.83 (<.001) 0.86 (<.001) 1.00
DMS 0.08 (.695) 0.09 (.639) 0.12 (.552) 1.00
% Total time 0.01 (.989) 0.07 (.718) 0.06 (.738) 0.98 (<.001) 1.00
NORE 0.03 (.869) 0.04 (.831) 0.08 (.696) 0.69 (<.001) 0.73 (<.001) 1.00
NOTE. Values are Spearman’s r (P value).
DMS, DeMeester score; NORE, number of reﬂux episodes; R&H, regurgitation and heartburn composite score.
Symptom scores were assessed using RDQ.
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